Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2014

01-05-2014 | Research Article

Differential expression of Pim-3, c-Myc, and p-p27 proteins in adenocarcinomas of the gastric cardia and distal stomach

Authors: Lei Lou, Yuan Wang, Jinfeng Cui, Xia Yan, Liying Xue, Yuehong Li

Published in: Tumor Biology | Issue 5/2014

Login to get access

Abstract

Gastric cardia adenocarcinoma (GCA) is distinct from adenocarcinoma of the distal stomach because of its different etiological factors, tumor characteristics, and biological behavior. However, its pathogenesis is not fully understood. The purpose of this study is to characterize the role of Pim-3, c-Myc, and p-p27 in the tumorigenesis and progression of different sites of gastric adenocarcinoma by determining its pathogenetic significance. The expression of Pim-3, c-Myc, and p-p27 proteins was evaluated by immunohistochemistry in 140 resection specimens of gastric adenocarcinomas (78 GCAs , 62 DGAs and 20 normal gastric tissues). The level of expression of Pim-3, c-Myc, and p-p27 and the co-expression of all three markers (Pim-3+/c-Myc+/p-p27+) in GCA were significantly lower than that in DGA tumors (P < 0.05). Detailed analysis of the immunoreactivity patterns showed that in DGA, Pim-3 immunoreactivity was associated significantly with poor tumor differentiation, advanced tumor stage, and presence of lymph node metastasis. In addition, c-Myc overexpression correlated with tumor stage and lymph node metastasis, and positive p-p27 expression correlated with poor differentiation and tumor stage. The phenotype of Pim-3+/c-Myc+/p-p27+ co-expression was closely correlated with tumor stage and lymph node metastasis (P < 0.05). In contrast, GCA only demonstrated a close correlation of Pim-3 overexpression with poor tumor differentiation and tumor stage (P < 0.05). Our results demonstrate the presence of different expression patterns of Pim-3, c-Myc, p-p27, and Pim-3+/c-Myc+/p-p27+ and their clinicopathologic significance in GCA and DGA tumors. Our results add support to the notion that distinct molecular mechanisms may be involved in the development and progression of adenocarcinomas from the gastric cardia and distal portion of stomach.
Literature
1.
Varadhachary G, Ajani JA. Gastric cancer. Clin Adv Hematol Oncol. 2005;3:118–24.PubMed
2.
Pera M. Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. Recent Results Cancer Res. 2000;155:1–14.CrossRefPubMed
3.
Richards DA, Boehm KA, Anthony SP. Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions. Expert Opin Investig Drugs. 2007;16:1059–68.CrossRefPubMed
4.
Zhao C, Zhang X, Xue L, Xing L, Wang J, Li X. Analysis of the changing trends of frequency and localization of gastric cancers arising fromdifferent sites of the stomach in population of the high incidence area of esophageal and gastriccancers in Hebei Province. Zhonghua Zhong Liu Za Zhi. 2008;30:817–20.PubMed
5.
Ichikura T, Ogawa T, Kawabata T, Chochi K, Sugasawa H, Mochizuki H. Is adenocarcinoma of the gastric cardia a distinct entity independent of subcardial carcinoma? World J Surg. 2003;27:334–8.CrossRefPubMed
6.
MacDonald WC, MacDonald JB. Adenocarcinoma of the esophagus and/or gastric cardia. Cancer. 1987;60:1094–8.CrossRefPubMed
7.
Gray JR, Coldman AJ, MacDonald WC. Cigarette and alcohol use in patients with adenocarcinoma of the gastric cardia or lower esophagus. Cancer. 1992;69:2227–31.CrossRefPubMed
8.
Yao D, Wang Y, Xue L, Wang H, Zhang J, Zhang X. Different expression pattern and significance of p14ARF-Mdm2-p53 pathway and Bmi-1 exist between gastric cardia and distal gastric adenocarcinoma. Hum Pathol. 2013;44:844–51.CrossRefPubMed
9.
Xue L, Zhang X, Li Y, Yang H, Li X, Mi J, et al. Differences of immunophenotypic markers and signaling molecules between adenocarcinomas of gastric cardia and distal stomach. Hum Pathol. 2011;42:594–601.CrossRefPubMed
10.
Mukaida N, Wang YY, Li YY. Roles of Pim-3, a novel survival kinase, in tumorigenesis. Cancer Sci. 2011;102:1437–42.CrossRefPubMed
11.
Zheng HC, Tsuneyama K, Takahashi H, Miwa S, Sugiyama T, Popivanova BK, et al. Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression. J Cancer Res Clin Oncol. 2008;134:481–8.CrossRefPubMed
12.
Forshell LP, Li Y, Forshell TZ, Rudelius M, Nilsson L, Keller U, et al. The direct Myc target Pim3 cooperates with other pim kinases in supporting viability of Myc-induced B-cell lymphomas. Oncotarget. 2011;2:448–60.CrossRefPubMedPubMedCentral
13.
Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 2008;68:5076–85.CrossRefPubMed
14.
Zhang L, Hou Y, Ashktorab H, Gao L, Xu Y, Wu K, et al. The impact of C-MYC gene expression on gastric cancer cell. Mol Cell Biochem. 2010;344:125–35.CrossRefPubMedPubMedCentral
15.
Lee KH, Lee HE, Cho SJ, Cho YJ, Lee HS, Kim JH, et al. Immunohistochemical analysis of cell cycle-related molecules in gastric carcinoma: prognostic significance, correlation with clinicopathological parameters, proliferation and apoptosis. Pathobiology. 2008;75:364–72.CrossRefPubMed
16.
Siewert JR, Holscher AH, Becker K, Gossner W. Cardia cancer: attempt at a therapeutically relevant classification. Chirurg. 1987;58:25–32.PubMed
17.
Siewert JR, Feith M, Stein HJ. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol. 2005;90:139–46. discussion 146.CrossRefPubMed
18.
Flejou JF. WHO classification of digestive tumors: the fourth edition. Ann Pathol. 2011;31:S27–31.CrossRefPubMed
19.
20.
Zhu S, Sun P, Zhang Y, Yan L, Luo B. Expression of c-myc and PCNA in epstein-barr virus-associated gastric carcinoma. Exp Ther Med. 2013;5:1030–4.PubMedPubMedCentral
21.
He SM, Zhao ZW, Wang Y, Zhao JP, Wang L, Hou F, et al. Potential role of Jun activation domain-binding protein 1 and phosphorylated p27 expression in prognosis of glioma. Brain Tumor Pathol. 2012;29:3–9.CrossRefPubMed
22.
Hammerman PS, Fox CJ, Birnbaum MJ, Thompson CB. Pim and akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood. 2005;105:4477–83.CrossRefPubMedPubMedCentral
23.
Li YY, Popivanova BK, Nagai Y, Ishikura H, Fujii C, Mukaida N. Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res. 2006;66:6741–7.CrossRefPubMed
24.
Popivanova BK, Li YY, Zheng H, Omura K, Fujii C, Tsuneyama K, et al. Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent bad-mediated apoptosis. Cancer Sci. 2007;98:321–8.CrossRefPubMed
25.
Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J. Pim serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica. 2010;95:1004–15.CrossRefPubMedPubMedCentral
26.
Wu Y, Wang YY, Nakamoto Y, Li YY, Baba T, Kaneko S, et al. Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver. Oncogene. 2010;29:2228–37.CrossRefPubMed
27.
ZF H, Y H, Q Z, J J: Significance of Pim-3 expression in gastric carcinoma. Shijie Huaren Xiaohua Zazhi 2008;16:3515-18.
28.
Zhang Y, Wang Z, Li X, Magnuson NS. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene. 2008;27:4809–19.CrossRefPubMed
29.
Beharry Z, Mahajan S, Zemskova M, Lin YW, Tholanikunnel BG, Xia Z, et al. The Pim protein kinases regulate energy metabolism and cell growth. Proc Natl Acad Sci U S A. 2011;108:528–33.CrossRefPubMed
30.
Zhang Y, Wang Z, Magnuson NS. Pim-1 kinase-dependent phosphorylation of p21cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res. 2007;5:909–22.CrossRefPubMed
31.
Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (t1a, b) invasive breast carcinomas. Cancer Res. 1997;57:1259–63.PubMed
32.
Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med. 1997;3:227–30.CrossRefPubMed
33.
Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997;3:231–4.CrossRefPubMed
34.
Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997;57:3381–5.PubMed
35.
Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 1998;58:542–8.PubMed
36.
Ohtani M, Isozaki H, Fujii K, Nomura E, Niki M, Mabuchi H, et al. Impact of the expression of cyclin-dependent kinase inhibitor p27Kip1 and apoptosis in tumor cells on the overall survival of patients with non-early stage gastric carcinoma. Cancer. 1999;85:1711–8.CrossRefPubMed
37.
Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol. 2003;13:41–7.CrossRefPubMed
38.
Allen JD, Verhoeven E, Domen J, van der Valk M, Berns A. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene. 1997;15:1133–41.CrossRefPubMed
39.
van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T, et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell. 1989;56:673–82.CrossRefPubMed
40.
Mikkers H, Allen J, Knipscheer P, Romeijn L, Hart A, Vink E, et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet. 2002;32:153–9.CrossRefPubMed
41.
Keller UB, Old JB, Dorsey FC, Nilsson JA, Nilsson L, MacLean KH, et al. Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. EMBO J. 2007;26:2562–74.CrossRefPubMedPubMedCentral
42.
Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, et al. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene. 2001;20:1688–702.CrossRefPubMed
43.
Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J. 1996;15:6595–604.PubMedPubMedCentral
44.
Muller D, Bouchard C, Rudolph B, Steiner P, Stuckmann I, Saffrich R, et al. Cdk2-dependent phosphorylation of p27 facilitates its myc-induced release from cyclin e/cdk2 complexes. Oncogene. 1997;15:2561–76.CrossRefPubMed
45.
Perez-Roger I, Kim SH, Griffiths B, Sewing A, Land H. Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J. 1999;18:5310–20.CrossRefPubMedPubMedCentral
46.
Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999;18:5321–33.CrossRefPubMedPubMedCentral
47.
Alves MK, Lima VP, Andre AR, Ferreira MV, Barros MA, Rabenhorst SH. p27KIP1 expression in gastric cancer: differential pathways in the histological subtypes associated with Helicobacter pylori infection. Scand J Gastroenterol. 2010;45:409–20.CrossRefPubMed
48.
Gulmann C, Hegarty H, Grace A, Leader M, Patchett S, Kay E. Differences in proximal (cardia) versus distal (antral) gastric carcinogenesis via the retinoblastoma pathway. World J Gastroenterol. 2004;10:17–21.PubMedPubMedCentral
Metadata
Title
Differential expression of Pim-3, c-Myc, and p-p27 proteins in adenocarcinomas of the gastric cardia and distal stomach
Authors
Lei Lou
Yuan Wang
Jinfeng Cui
Xia Yan
Liying Xue
Yuehong Li
Publication date
01-05-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1664-z

Other articles of this Issue 5/2014

Tumor Biology 5/2014 Go to the issue

Research Article

HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc

Research Article

Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group

Research Article

ARID1A: a potential prognostic factor for breast cancer

Research Article

CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes

Research Article

Association of single nucleotide polymorphisms of nucleotide excision repair genes with laryngeal cancer risk and interaction with cigarette smoking and alcohol drinking

Research Article

Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits